Bridgeway Capital Management’s Pacira BioSciences PCRX Stock Holding History

Bridgeway Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.3M	Sell	411,373 -29,832	-7%	-$663K	0.19%	162
2025 Q4	$11.4M	Sell	441,205 -3,533	-0.8%	-$84K	0.24%	121
2025 Q3	$11.5M	Sell	444,738 -15,535	-3%	-$382K	0.24%	125
2025 Q2	$11M	Buy	460,273 +31,744	+7%	+$800K	0.26%	110
2025 Q1	$10.6M	Buy	428,529 +69,744	+19%	+$1.67M	0.27%	108
2024 Q4	$6.76M	Buy	358,785 +11,149	+3%	+$196K	0.15%	201
2024 Q3	$5.23M	Buy	+347,636	New	+$5.94M	0.11%	266
2021 Q4	–	Sell	-8,300	Closed	-$465K	–	1316
2021 Q3	$465K	Buy	+8,300	New	+$478K	0.01%	1056

Other funds holding PCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return